Ovarian Cancer Therapeutics Global Market is Rise at a Limited CAGR of 3.4% to $1.9billion in 2020, Reveals New Report

“Ovarian Cancer Therapeutics in Major Developed Markets to 2020 Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies”, The current Ovarian cancer therapeutics market is dominated by the use of generics – predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission. However, even with extended progression free-survival of 24 months, almost all patients relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor.

There is a clear gap in the market for maintenance therapies to extend the initial high rates of remission, and hopefully stimulate long-term remission in patients. As well as a gap for more effective treatment options in platinum-resistant or refractory patients.

The current developmental pipeline addresses these gaps in the market, with five of the 10 late stage pipeline molecules indicated as maintenance therapies, and three of the 10 indicated in platinum-resistant disease. However, efficacy with these late stage drugs has been poor, at best demonstrating minimal improvements in PFS. In the EU, both Avastin and Yondelis have been approved on the basis of improvements in PFS alone. It is expected therefore, that those pipeline drugs that have demonstrated the most significant improvements in PFS – olaparib, Vynfinit and trebananib, will be approved in this territory. However even on approval, the lack of an overwhelming improvement in clinical benefit with these drugs, and their expected high cost will limit their sales. In the US, the improvement in PFS observed with Yondelis and Avastin, in the absence of any other clinical benefit with either drug, resulted in neither drug being approved by the FDA. In line with these rejections, the improvements in PFS alone, observed with the current late stage pipeline drugs, is expected to result in the failure of any drug to be approved in the US within the forecast period.

As a result the global market is expected not be driven by new drug approvals, but primarily inflation, and the increase in the prevalence of pancreatic cancer. Global market revenues are forecast to rise at a limited CAGR of 3.4% to $1.9billion in 2020.

Despite the poor results obtained with late stage pipeline drugs there is evidence of continued interest in the ovarian cancer market, with a high number of drug candidates in the current developmental pipeline, particularly at the Preclinical Phase. There is a wide range of novel molecular targets distributed amongst these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in other indications in oncology.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for pancreatic cancer. The report covers and includes:

• A brief introduction to ovarian cancer, including the disease’s pathogenesis, risk factors and diagnosis.
• In-depth analysis of the drug combinations used in the treatment of ovarian cancer, including analyses of their safety, efficacy, and place in the disease treatment algorithm. This includes a heat map comparing the drug combination in terms of safety and efficacy.
• Comprehensive review of the pipeline for ovarian cancer therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.
• Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
• Multi-scenario forecast data of the market to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Canada, Japan, Germany, the UK, France, Italy and Spain.
• Discussion of the drivers and barriers for market growth.
• An in-depth analysis of licensing and co-development deals involving drugs indicated in ovarian cancer, including an in-depth outline of the key deals.

Reasons to buy

• The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to
• Understanding the efficacy and safety of the current monotherapies and drug combinations used in the treatment of ovarian cancer, with an in-depth analysis of the disease treatment algorithm.
• Understand the key signalling pathways and molecular targets currently inder investigation in drug development for ovarian cancer
• Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
• Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for pancreatic cancer therapeutics.
• Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the ovarian cancer therapeutics market.

Spanning over 148 pages, “Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies” report covering the Introduction,  Marketed Products, Product Pipeline, Late-Stage Drugs in Developmental Pipeline, Market Forecast, Drivers and Barriers, Deals, Appendix.

Know more about this report: http://mrr.cm/ZNK